Myocet liposomal (previously Myocet)
doxorubicin
Table of contents
Overview
Myocet liposomal is a cancer medicine for use with cyclophosphamide (another cancer medicine) to treat women with metastatic breast cancer. ‘Metastatic’ means that the cancer has spread to other parts of the body.
Myocet liposomal contains the active substance doxorubicin.
Authorisation details
Product details | |
---|---|
Name |
Myocet liposomal (previously Myocet)
|
Agency product number |
EMEA/H/C/000297
|
Active substance |
doxorubicin hydrochloride
|
International non-proprietary name (INN) or common name |
doxorubicin
|
Therapeutic area (MeSH) |
Breast Neoplasms
|
Anatomical therapeutic chemical (ATC) code |
L01DB01
|
Publication details | |
---|---|
Marketing-authorisation holder |
Teva B.V.
|
Revision |
24
|
Date of issue of marketing authorisation valid throughout the European Union |
13/07/2000
|
Contact address |
Swensweg 5 |
Product information
15/12/2022 Myocet liposomal (previously Myocet) - EMEA/H/C/000297 - II/0070
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antineoplastic agents
Therapeutic indication
Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.